دورية أكاديمية
أعرض في EDS

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.

التفاصيل البيبلوغرافية
العنوان: Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
المؤلفون: Rosen VM; Optum, Eden Prairie, MN; †Mapi Group, Uxbridge; and ‡University College London Hospitals, London, UK; §Federal University, Belo Horizonte; and ∥State University of Campinas, Campinas, Brazil; and ¶F. Hoffmann-La Roche Ltd, Basel, Switzerland., Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk VC, Shang A
المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2017 Jul; Vol. 27 (6), pp. 1237-1246.
نوع المنشور: Journal Article; Meta-Analysis; Review; Systematic Review
اللغة: English
بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Print Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2019- : [London] : BMJ
Original Publication: Cambridge, MA, USA : Blackwell Scientific Publications, c1991-
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Neoplasm Recurrence, Local/*drug therapy , Uterine Cervical Neoplasms/*drug therapy, Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bevacizumab/administration & dosage ; Cisplatin/administration & dosage ; Female ; Humans ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/pathology ; Paclitaxel/administration & dosage ; Topotecan/administration & dosage ; Uterine Cervical Neoplasms/pathology
مستخلص: Objective: Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of bevacizumab to paclitaxel-topotecan or paclitaxel-cisplatin has been shown to prolong survival compared with paclitaxel-topotecan or paclitaxel-cisplatin in patients with persistent, recurrent, or metastatic disease. However, standards of care vary between regions and countries. The purpose of this systematic review and network meta-analysis was to enable a comparison between bevacizumab + chemotherapy with multiple monotherapy or combination chemotherapy regimens in the treatment for women with advanced, recurrent, or persistent cervical cancer.
Methods/materials: A systematic literature review was conducted to identify randomized or nonrandomized controlled trials of patients with recurrent, persistent, or metastatic cervical cancer published in English from 1999 to 2015. A feasibility study was performed to assess the heterogeneity of the trials, and a network meta-analysis was conducted. Fixed- and random-effects models were fitted to calculate the hazard ratio for overall survival (OS) for all pairwise comparisons and ranking of all interventions.
Results: Twenty-three studies (19 trials) met inclusion criteria and were included in the review. Sample sizes ranged from 69 to 452, and median patient age ranged from 45 to 53 years. There was a trend toward prolonged OS with cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab compared with all non-bevacizumab-containing therapies. Cisplatin-paclitaxel-bevacizumab had the highest probability of being the most efficacious compared with all regimens (68.1%), and cisplatin monotherapy had the lowest (0%).
Conclusions: The results of this network meta-analysis show that bevacizumab in combination with paclitaxel-topotecan or paclitaxel-cisplatin is likely to prolong OS over other non-bevacizumab-containing chemotherapies (eg, paclitaxel-carboplatin), which were not included in the GOG240 trial. In patients with advanced, persistent, and recurrent cervical cancer, cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab showed the highest efficacy in all regimens investigated in this analysis.
References: Gynecol Oncol. 2010 Dec;119(3):531-7. (PMID: 20837359)
J Clin Oncol. 2005 Jul 20;23(21):4617-25. (PMID: 15911864)
Invest New Drugs. 2003 Nov;21(4):453-7. (PMID: 14586213)
Gynecol Oncol. 2006 Mar;100(3):537-43. (PMID: 16216315)
Gynecol Oncol. 2006 May;101(2):296-304. (PMID: 16376417)
J Clin Oncol. 2010 Aug 1;28(22):3562-9. (PMID: 20606083)
J Clin Oncol. 2005 Jul 20;23(21):4626-33. (PMID: 15911865)
N Engl J Med. 2014 Feb 20;370(8):734-43. (PMID: 24552320)
BMC Med Res Methodol. 2010 Jun 10;10:54. (PMID: 20537177)
Gynecol Obstet Invest. 2005;59(3):126-9. (PMID: 15604591)
Gynecol Oncol. 2014 Apr;133(1):117-23. (PMID: 24486604)
J Clin Oncol. 2002 Apr 1;20(7):1832-7. (PMID: 11919241)
J Clin Oncol. 2009 Oct 1;27(28):4649-55. (PMID: 19720909)
Onco Targets Ther. 2015 Nov 19;8:3425-31. (PMID: 26640382)
Stat Med. 2004 Oct 30;23(20):3105-24. (PMID: 15449338)
Indian J Palliat Care. 2014 Sep;20(3):208-11. (PMID: 25191008)
J Clin Oncol. 2015 Jul 1;33(19):2129-35. (PMID: 25732161)
Am J Obstet Gynecol. 2016 Jan;214(1):22-30. (PMID: 26212178)
J Clin Epidemiol. 1997 Jun;50(6):683-91. (PMID: 9250266)
Int J Gynecol Cancer. 2006 May-Jun;16(3):1172-8. (PMID: 16803502)
J Clin Oncol. 2004 Aug 1;22(15):3113-9. (PMID: 15284262)
Ann Oncol. 2009 Aug;20(8):1362-8. (PMID: 19457937)
Med Oncol. 2011 Dec;28 Suppl 1:S540-6. (PMID: 20931299)
Ann Oncol. 2012 Oct;23 Suppl 7:vii27-32. (PMID: 22997451)
Clin Transl Oncol. 2015 Dec;17 (12 ):1036-42. (PMID: 26650487)
Ann Oncol. 2001 Jul;12(7):967-74. (PMID: 11521804)
World J Clin Oncol. 2015 Dec 10;6(6):281-90. (PMID: 26677441)
معلومات مُعتمدة: United Kingdom Wellcome Trust
المشرفين على المادة: 2S9ZZM9Q9V (Bevacizumab)
7M7YKX2N15 (Topotecan)
P88XT4IS4D (Paclitaxel)
Q20Q21Q62J (Cisplatin)
SCR Protocol: TP protocol
تواريخ الأحداث: Date Created: 20170428 Date Completed: 20180206 Latest Revision: 20181202
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC5499964
DOI: 10.1097/IGC.0000000000001000
PMID: 28448304
قاعدة البيانات: MEDLINE
الوصف
تدمد:1525-1438
DOI:10.1097/IGC.0000000000001000